Kodiak Sciences (KOD) Times Interest Earned (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Times Interest Earned came in at -$0.13 in Q1 2026, up 99.59% YoY from -$0.06 in Q1 2025, and up 26.45% on a QoQ basis from -$0.18 in Q4 2025.
Kodiak Sciences (KOD) Times Interest Earned (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Times Interest Earned data on file, last reported at -$0.13 in Q1 2026.
- Quarterly Times Interest Earned rose 99.59% year-over-year to -$0.13 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.51 (up 99.52% YoY) and the FY2025 annual result came in at -$0.71, up 5.53% from the prior year.
- Times Interest Earned improved to -$0.13 in Q1 2026, from -$0.18 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.13 in Q1 2026 to a low of -$18516.5 in Q4 2022.
- A 5-year average of -$1117.3 and a median of -$16.89 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned slumped 17227.6% — and 2023, when it surged 99.98%.
- Tracing KOD's Times Interest Earned over 5 years: stood at -$18516.5 in 2022, then surged by 99.98% to -$4.18 in 2023, then slumped by 1126.12% to -$51.31 in 2024, then surged by 99.66% to -$0.18 in 2025, then advanced by 26.45% to -$0.13 in 2026.
- The last three Times Interest Earned figures came in at -$0.13 (Q1 2026), -$0.18 (Q4 2025), and -$0.37 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - | -0.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.15 |
| Mar 31, 2026 | -0.13 |
| Dec 31, 2025 | -0.18 |
| Sep 30, 2025 | -0.37 |
| Jun 30, 2025 | -9.61 |
| Mar 31, 2025 | -31.14 |
| Dec 31, 2024 | -51.31 |
| Sep 30, 2024 | -39.19 |
| Jun 30, 2024 | -80.78 |
| Mar 31, 2024 | -22.25 |
| Dec 31, 2023 | -4.18 |
| Sep 30, 2023 | -159.36 |
| Jun 30, 2023 | -16.89 |
| Mar 31, 2023 | -21.29 |
| Dec 31, 2022 | -18,516.50 |
| Sep 30, 2022 | -11.97 |
| Jun 30, 2022 | -14.29 |
| Mar 31, 2022 | -14.57 |
| Dec 31, 2021 | -18,609.80 |
| Sep 30, 2021 | -0.16 |